Publications by authors named "Felix Klimek"
Article Synopsis
- Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition often treated with the anti-IL-5 antibody mepolizumab, which was approved as an additional therapy in 2021 when other treatments fail.
- Current guidelines for using mepolizumab in CRSwNP lack detailed instructions on monitoring, documentation, and discontinuation protocols.
- A literature review led to recommendations for following up on treatment, ensuring adherence to therapy schedules, and guidance on possible therapy interruptions or discontinuation for patients under the German healthcare system.
Introduction: Eosinophils play an important regulatory and immunomodulatory role in airway mucosa and have antiparasitic and antiviral properties as well as pro-inflammatory effects that may also cause persistence of inflammation with tissue remodeling. The number of eosinophils and the detection of specific mediators in biological samples from, e.g.
View Article and Find Full Text PDFIntroduction: Eosinophilic granulomatosis with polyangiitis (EGPA) was formerly known as Churg-Strauss syndrome. The condition is characterized by disseminated necrotizing vasculitis with extravascular granulomas associated with hypereosinophilia. The vasculitides affect small vessels and are associated with antineutrophil cytoplasmic antibodies (ANCAs) detectable in the blood.
View Article and Find Full Text PDFLoss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment.
View Article and Find Full Text PDFBackground: The epithelial immune regulation is an essential and protective feature of the barrier function of the mucous membranes of the airways. Damage to the epithelial barrier can result in chronic inflammatory diseases, such as chronic rhinosinusitis (CRS) or bronchial asthma. Thymic stromal lymphopoietin (TSLP) is a central regulator in the epithelial barrier function and is associated with type 2 (T2) and non-T2 inflammation.
View Article and Find Full Text PDF